

Raptor Pharmaceutical Corp  
Form 8-K  
July 29, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 28, 2014**

**RAPTOR PHARMACEUTICAL CORP.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation)**

**000-25571**  
**(Commission File Number)**

**86-0883978**  
**(IRS Employer Identification**  
**Number)**

**7 Hamilton Landing, Suite 100**

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

**Novato, California 94949**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (415) 408-6200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) Effective July 28, 2014, each of Vijay B. Samant and Timothy P. Walbert resigned from the Board of Directors of Raptor Pharmaceutical Corp. (the Company). Each of Mr. Samant's and Mr. Walbert's decision to resign as a director did not involve any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**RAPTOR PHARMACEUTICAL CORP.**

Date: July 28, 2014

By: /s/ Georgia Erbez  
Name: Georgia Erbez  
Title: Chief Financial Officer, Secretary and Treasurer